bioRxiv Science⌕ Search

Biology subjects

Tang, R. S.

Publications and source records attributed to Tang, R. S..

3 recordsLinked to original sources

LLM-powered automatic scoring tools for memory recall

Free recall of naturalistic stimuli, such as films and stories, reveals what people remember and how they organize it. Scoring such recall requires matching each recalled utterance to the encoded stimulus, and doing this manually often makes large studies impractical. Existing automated methods mostly return similarity or aggregate scores rather than explicit matches between recalled and stimulus content. Here we introduce an open-source, model-agnostic pipeline that uses a large language model (LLM) to divide the stimulus and the recall into information units and to match units between the two texts. The output is a table of unit-to-unit matches with accuracy labels, from which standard analysis scripts compute recall measures. We validated the pipeline with four LLMs (Claude Sonnet 4.5, GPT 5.4, Gemini 2.5 Pro, and Gemini 2.5 Flash) on three datasets. On typed recall of four short stories, agreement between each model and two trained raters ({phi} = .73-.79) was close to the agreement between the raters themselves ({phi} = .77). A second run reproduced each model's matches ({phi} = .91-.97) more closely than the raters agreed with each other. On spoken recall of 10 films, every model attributed recall to the correct film with high agreement. On uncorrected speech-to-text recall of a television episode, agreement varied more across models. The median cost was under $1 per participant for every model. These results suggest that the pipeline can serve as a reliable, low-cost alternative to manual scoring of free recall.

neuroscience↗

Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection

The emergence of new SARS-CoV-2 variants and breakthrough infections underscores the need for next-generation vaccines capable of protecting from natural infection and/or preventing virus transmission to others. Intranasal vaccination offers a promising approach by eliciting local immune responses in the nasal mucosa, the primary site of infection and reservoir for transmissible virus. We evaluated two live-attenuated, respiratory syncytial virus vectored vaccines in which the RSV F and G surface glycoproteins were replaced with a chimeric SARS-CoV-2 Spike protein from either the ancestral USA/WA-1/2020 strain (MV-014-212) or the Delta variant (MV-014-212-delta). A single intranasal dose of either vaccine elicited systemic and mucosal immunity in K18-hACE2 mice, including serum neutralizing antibodies, Spike-specific memory B cells and plasmablasts, and Spike-specific CD8 lung-resident memory T cells. Although MV-014-212-delta vaccination provided the best protection against Delta variant virus challenge, both vaccines decreased viral loads in nasal discharge, lung and brain, and reduced weight loss and mortality. In naturally acquired infection studies, vaccinated hamsters exposed to infected cagemates exhibited minimal weight loss, limited viral replication within the nasal mucosa, and attenuated lung pathology. Therefore, intranasal RSV-vectored vaccines can elicit broad protective respiratory immunity, suggesting that this platform could be leveraged for other respiratory pathogens.

immunology↗

One mucosal administration of a live attenuated recombinant COVID-19 vaccine protects non-human primates from SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein, spike, for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live attenuated, recombinant human respiratory syncytial virus (RSV) expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200- fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunity in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against two virus variants of concern. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in phase 1 clinical trials as a single-dose intranasal COVID-19 vaccine.

immunology↗